Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Will the Pharma Space Witness More Mega-Merger Deals in 2H?
by Kinjel Shah
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
by Zacks Equity Research
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Company News for Jul 2, 2019
by Zacks Equity Research
Companies In The News Are: BA,GWR,BIP,PFE,COTY
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
by Zacks Equity Research
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Company News for Jul 1, 2019
by Zacks Equity Research
Companies In The News Are: PFE,NKE,AAPL,STZ
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
by Zacks Equity Research
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop
by Swarup Gupta
The index suffered a disappointing week, declining over three straight trading sessions
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
by Zacks Equity Research
Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.
Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits
by Zacks Equity Research
Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.
Conatus' Emricasan Lags Primary Goal in Liver Function Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.
Pfizer (PFE) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.76, marking no change from the previous day.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Eldorado to Buy Caesars
by Zacks Equity Research
Eldorado to Buy Caesars
BioMarin Gets $15M From Pfizer on Talzenna's European Nod
by Zacks Equity Research
BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.
U.S. Senate Takes on Big Tech, Plus "Merger Monday"
by Mark Vickery
Eldorado Resorts (ELR) has agreed to buy Caesars (CZR) for $8.6 billion, and a bipartisan bill in the Senate holds Big Tech accountable for monetized user data.
Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
by Zacks Equity Research
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
by Swarup Gupta
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.